openPR Logo
Press release

Preimplantation Genetic Diagnosis Market to Witness Robust Expansion Throughout the Forecast Period 2014 - 2020

02-24-2017 02:05 PM CET | IT, New Media & Software

Press release from: TMR - Research Reports

Preimplantation Genetic Diagnosis Market to Witness Robust

Preimplantation genetic diagnosis (PGD) is an adjuvant technique to in vitro fertilization (IVF) for detecting genetic diseases or conditions before the implantation of embryo. PGD can be performed for screening of a range of medical conditions such as Down’s syndrome, inheritable diseases and traits of other physiological abnormality. Increasing patient awareness about PGD technique and rising prevalence of genetic disorders among infants has led to the rise in demand for PGD along with IVF procedure. The combination of PGD and IVF has improved the rate of successful pregnancy due to reduced chances of passing the undesired genetic material in the embryo.

Obtain the PDF containing Upcoming Market Trends of Preimplantation Genetic Diagnosis at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=427

The use of array comparative genomic hybridization (aCGH) and fluorescent in situ hybridization (FISH) techniques in PGD has improved the process efficiency and success rate of pregnancy through IVF. Demand for PGD, however, is dependent on the regulations governing infertility procedures in various countries. PGD for gender selection and HLA typing is banned in most parts of Asia, whereas it is regulated in the U.S. and in some parts of the European Union. Regulatory impact plays a major role in analyzing the global preimplantation genetic diagnosis market.

Based on the type of test, the global preimplantation genetic diagnosis market has been categorized into six segments: PGD for chromosomal aberrations, PGD for aneuploidy screening, PGD for gender selection, PGD for single gene disorder, PDG for HLA typing and PGD for X-linked diseases. PGD for aneuploidy screening held the highest share in 2013 as aneuploidy could lead to severe abnormalities. Aneuploidy screening reduces the probability of transferring an embryo with chromosomal abnormality. . Aneuploidy screening during prenatal testing has a major disadvantage; if the chromosomal abnormality were detected in the fetus, the pregnancy would be terminated. However, this drawback is efficiently overcome by opting for preimplantation genetic diagnosis, since genetic screening for aneuploidy is performed before the embryo is implanted and pregnancy is conceived.

Geographically, the global preimplantation genetic diagnosis market has been categorized into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW). Each geographical market has been further analyzed based on the types of test. Europe dominated the global preimplantation genetic diagnosis market in 2013 due to increasing patient awareness and high number of IVF cycles being performed in the region. Conversely, North America is expected to grow at a higher CAGR during the forecast period due to rapid increase in the number of IVF cycles being performed and the rising disability rate due to increase in smoking. Moreover, high cost of the gender selection procedure and rising demand for identifying and selecting the gender by mothers increases the market share of PGD in gender selection. Restrictions on gender selection and detection of X-linked diseases in developing regions such as Asia Pacific, Latin America and Africa restrain the growth of the PGD market. Moreover, lack of patient awareness and inadequate healthcare facilities in the developing economies of these regions limit the use of PGD in HLA typing and detection of single gene disorder.

Read the Present Market Status of Preimplantation Genetic Diagnosis at: http://www.transparencymarketresearch.com/preimplantation-genetic-diagnosis-market.html

The global preimplantation genetic diagnosis market is characterized by the presence of some of the major companies including Genesis Genetics, Genea Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics, Inc., Reprogenetics LLC and Reproductive Genetics Institute. Market players are in constant endeavor to improve their technologies in genetic testing in order to enhance the efficiency and provide better services to healthcare practitioners.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Preimplantation Genetic Diagnosis Market to Witness Robust Expansion Throughout the Forecast Period 2014 - 2020 here

News-ID: 448186 • Views:

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2024
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1.07 Billion by 2024
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million by 2024
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for PGD

Preimplantation Genetics Diagnosis (PGD) Market Key Findings, Growth Strategy, T …
Preimplantation Genetics Diagnosis (PGD) Market - Overview The size of the preimplantation genetics diagnosis (PGD) market has been estimated to grow at a significant speed in the forthcoming years. This rapid growth in the market is on the basis of the high accuracy of the PGD in order to detect genetic disorders. In addition to this, increasing investment to detect genetic disorders along with chromosomal abnormalities around the world is also
Preimplantation Genetics Diagnosis (PGD) Market Current Scenario Trends, Compreh …
Preimplantation Genetics Diagnosis (PGD) Market - Overview The size of the preimplantation genetics diagnosis (PGD) market has been estimated to grow at a significant speed in the forthcoming years. This rapid growth in the market is on the basis of the high accuracy of the PGD in order to detect genetic disorders. In addition to this, increasing investment to detect genetic disorders along with chromosomal abnormalities around the world is also
Preimplantation Genetics Diagnosis (PGD) Market: Increasing Demand for Efficient …
The world PGD market is expected to witness notable growth in the coming years owning to the rising prevalence of genetic, hereditary and chromosomal diseases. Moreover, PGD have high chances of conceiving healthy embryos. However, the high costs incurred in the PGD technologies hamper the growth of the market. Moreover, stringent government regulations and ethical concerns also obstruct the growth of the market. In coming years, there would be increase
01-20-2020 | Health & Medicine
CRIFAX
Preimplantation Genetic Diagnosis (PGD) Market – Industry Growth Analysis & Fo …
CRIFAX added a report on ‘Preimplantation Genetic Diagnosis (PGD) Market Analysis Report, Global Outlook (U.S., Canada, UK, Germany, France, Italy, Spain, Netherlands, Russia, China, India, Japan, Australia, South Korea, Malaysia, Brazil, Mexico, Argentina, GCC, South Africa), Growth Potential, Competitive Market Share & Forecast, 2019 – 2028’to its database of market research collaterals consisting of overall market scenario with prevalent and future growth prospects, among other growth strategies used by key
Global Preimplantation Genetic Diagnosis (PGD) Market is Anticipated to Reach US …
A new Transparency Market Research report states that the global preimplantation genetic diagnosis (PGD) market stood at US$77.2 mn in 2013 and is anticipated to reach US$118 mn by 2020, by expanding at a CAGR of 6.28% from 2014 to 2020. The title of the report is “Preimplantation Genetic Diagnosis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020.” Preimplantation genetic diagnosis (PGD) is the genetic
Global Preimplantation Genetic Diagnosis Market (PGD) to Reach $121.50 Million b …
Market Research Reports Search Engine (MRRSE) has been serving as an active source to cater intelligent research report to enlighten both readers and investors. This research study titled “Preimplantation Genetic Diagnosis Market “ Get Free Sample Report @ https://www.mrrse.com/sample/1351 Since the last two decades, preimplantation genetic diagnosis (PGD) has been used to detect chromosomal aneuploidy in low prognosis patients who undergo in-vitro fertilization (IVF). PGD is now being used to detect a broader